Polycythaemia Vera — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Monocyte-To-Lymphocyte Ratio as a Predictor of Thrombosis Progression in Patients With Polycythemia Vera: A Retrospective Study.
Abdelfattah Ali et al. — International journal of laboratory hematology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41213725/
- 2.
Polycythemia vera.
Ellis Martin H et al. — Mayo Clinic proceedings (28 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41902804/
- 3.
Risk factors for leukemic transformation in myeloproliferative neoplasms and prognostic factors in secondary acute myeloid leukemia: an exploratory analysis of the SEER database.
Wang Shuainan et al. — Annals of hematology (25 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41876777/
- 4.
[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].
Zhang Y H et al. — Zhonghua yi xue za zhi (24 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41856608/
- 5.
Non-cirrhotic portal-splenic-mesenteric vein thrombosis unmasking JAK2 V617F-positive polycythemia vera.
Otake Tomoki et al. — Clinical journal of gastroenterology (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41870701/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Recruiting — Phase 1 — Disc Medicine, Inc
https://clinicaltrials.gov/study/NCT05320198
- 2.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06351631
- 3.
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Recruiting — Phase 1 — Incyte Corporation
https://clinicaltrials.gov/study/NCT07441694
- 4.
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Recruiting — Phase 3 — Swedish Orphan Biovitrum
https://clinicaltrials.gov/study/NCT03165734
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Polycythaemia Vera
Polycythaemia Vera is a myeloproliferative neoplasm in which the bone marrow overproduces red blood cells, causing blood thickening and increased clotting risk. It is almost universally driven by the JAK2 V617F mutation. Management includes phlebotomy, aspirin, and cytoreductive therapy with hydroxyurea or ruxolitinib. The primary risk is thrombosis and transformation to myelofibrosis.
Most Recent Research
INTRODUCTION: Thrombosis is a leading cause of mortality in polycythemia vera (PV), yet little is known about early predictors of thrombosis progression. Emerging evidence links systemic inflammation to thrombosis risk. This study assessed hematological inflammatory parameters, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI), for their utility in predicting thrombosis progression in PV. METHODS: This retrospective study analyzed 102 PV patients (2008-2024) and 115 healthy controls. Clinical and laboratory data, including thrombotic events, were examined. Patients were stratified into low-and high-risk groups, further categorized by thrombosis progression. Inflammatory biomarkers were derived from baseline blood counts. RESULTS: Median follow-up was 51 months, the 10-year thrombotic events-free survival rate was 84.30%, and 21 patients (20.59%) showed thrombosis progression. PV patients had higher NLR, MLR, PLR, SII, SIRI, and AISI than controls. NLR, MLR, SIRI, and AISI were associated with an increased risk of thrombosis compared to the low-risk group. In the progression group, high monocytes, NLR, MLR, SIRI, AISI, and previous thrombosis were notably correlated. ROC analysis showed that MLR (AUC = 0.739), SIRI (AUC = 0.714), AISI (AUC = 0.670), and NLR (AUC = 0.649) had the highest predictive ability for thrombosis progression. Multivariate analysis identified MLR (HR = 6.979) and previous thrombosis (HR = 4.494) as independent risk factors. CONCLUSION: These findings support recent reports linking systemic inflammation to thrombosis risk in PV patients and highlight for the first time that MLR may serve as a valuable prognostic biomarker for thrombotic events.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.